Praxis Precision Medicines Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.27
- Today's High:
- $1.39
- Open Price:
- $1.27
- 52W Low:
- $0.79
- 52W High:
- $5.25
- Prev. Close:
- $1.28
- Volume:
- 411422
Company Statistics
- Market Cap.:
- $201.81 million
- Book Value:
- 0.822
- Revenue TTM:
- $1.46 million
- Operating Margin TTM:
- -10914.89%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -63.63%
- Return on Equity TTM:
- -128.33%
Company Profile
Praxis Precision Medicines Inc had its IPO on 2020-10-16 under the ticker symbol PRAX.
The company operates in the Healthcare sector and Biotechnology industry. Praxis Precision Medicines Inc has a staff strength of 109 employees.
Stock update
Shares of Praxis Precision Medicines Inc opened at $1.27 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.27 - $1.39, and closed at $1.37.
This is a +7.03% increase from the previous day's closing price.
A total volume of 411,422 shares were traded at the close of the day’s session.
In the last one week, shares of Praxis Precision Medicines Inc have slipped by -12.74%.
Praxis Precision Medicines Inc's Key Ratios
Praxis Precision Medicines Inc has a market cap of $201.81 million, indicating a price to book ratio of 1.1157 and a price to sales ratio of 0.
In the last 12-months Praxis Precision Medicines Inc’s revenue was $1.46 million with a gross profit of $0 and an EBITDA of $-159375008. The EBITDA ratio measures Praxis Precision Medicines Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Praxis Precision Medicines Inc’s operating margin was -10914.89% while its return on assets stood at -63.63% with a return of equity of -128.33%.
In Q2, Praxis Precision Medicines Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Praxis Precision Medicines Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.18 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Praxis Precision Medicines Inc’s profitability.
Praxis Precision Medicines Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.0116. Its price to sales ratio in the trailing 12-months stood at 0.
Praxis Precision Medicines Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $133.50 million
- Total Liabilities
- $24.43 million
- Operating Cash Flow
- $5.00 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Praxis Precision Medicines Inc ended 2024 with $133.50 million in total assets and $0 in total liabilities. Its intangible assets were valued at $133.50 million while shareholder equity stood at $105.63 million.
Praxis Precision Medicines Inc ended 2024 with $0 in deferred long-term liabilities, $24.43 million in other current liabilities, 13000.00 in common stock, $-602411000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $124.30 million and cash and short-term investments were $124.30 million. The company’s total short-term debt was $1,064,000 while long-term debt stood at $0.
Praxis Precision Medicines Inc’s total current assets stands at $129.83 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $8.01 million and inventory worth $0.
In 2024, Praxis Precision Medicines Inc's operating cash flow was $5.00 million while its capital expenditure stood at $0.
Comparatively, Praxis Precision Medicines Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.37
- 52-Week High
- $5.25
- 52-Week Low
- $0.79
- Analyst Target Price
- $6.5
Praxis Precision Medicines Inc stock is currently trading at $1.37 per share. It touched a 52-week high of $5.25 and a 52-week low of $5.25. Analysts tracking the stock have a 12-month average target price of $6.5.
Its 50-day moving average was $1.21 and 200-day moving average was $1.77 The short ratio stood at 5.66 indicating a short percent outstanding of 0%.
Around 837.9% of the company’s stock are held by insiders while 7349.6% are held by institutions.
Frequently Asked Questions About Praxis Precision Medicines Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson’s disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.